Results:
The simulated PK profiles suggest no dose adjustments are required based
on age and race for COVID-19 drugs; however, sometimes dose adjustments
are warranted for patients exhibiting hepatic/renal impairment in
addition to COVID-19 co-morbidity. PBPK model simulations suggest ELF
exposure to attain a target concentration was adequate for most drugs
except azithromycin, atazanavir and lopinavir/ritonavir.